Back    Zoom +    Zoom -
CN Aims to Ramp Up Support for Biomanufacturing Industry Innovation & Development During 15th 5-Yr Plan: NMPA
Recommend
55
Positive
89
Negative
25
China's National Medical Products Administration (NMPA) announced that it is poised to vigorously support the innovation and development of the biomanufacturing industry during the 15th Five-Year Plan.

Specifically, the NMPA will closely monitor new target and mechanism drugs, AI-driven drug R&D, and frontier technology fields like cell and gene therapy this year. It will also expedite the process for drug market entry through four accelerated approval channels.

Related NewsCICC Raises CSPC PHARMA (01093.HK) TP to $12, Anticipates Continued Out-licensing Realization

AAStocks Financial News